Antithrombotic therapy for venous thromboembolic disease.
about
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonMeta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgeryDiagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice GuidelinesGuidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolismMeta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stentingTackling the devastating effects of heparin-induced thrombocytopenia.Management of patients with acute venous thromboembolism: findings from the RIETE registry.Current issues in anticoagulation.The role of ximelagatran in the treatment of venous thromboembolism.Five-year follow-up of pulmonary embolism under anticoaugulation: The PISA-PEET (Pulmonary Embolism Extension Therapy) studyAmbulation after deep vein thrombosis: a systematic reviewAnticoagulation for the acute management of ischemic strokeDeep vein thrombosis: a clinical review.New developments in the prevention and treatment of venous thromboembolism.Differentiation of the low-molecular-weight heparins.Venous thrombosis and anticoagulant therapy.The management of coumarin-induced over-anticoagulation Annotation.Evaluation of GenoFlow Thrombophilia Array Test Kit in its detection of mutations in Factor V Leiden (G1691A), prothrombin G20210A, MTHFR C677T and A1298C in blood samples from 113 Turkish female patients.Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.Evaluation of a potential tigecycline-warfarin drug interaction.Therapeutic equivalency of low-molecular-weight heparins.The hypercoagulable states in anaesthesia and critical careA survey of physicians' knowledge and management of venous thromboembolism.Long-term, low-intensity warfarin after idiopathic venous thromboembolism.Increase in venous complications associated with etomidate use during a propofol shortage: an example of clinically important adverse effects related to drug substitutionLow-molecular-weight heparins: are they all the same?Hypercoagulable state testing and malignancy screening following venous thromboembolic events.Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis.Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.British Thoracic Society guidelines for the management of suspected acute pulmonary embolismDuration of anticoagulant therapy after initial idiopathic venous thromboembolism.Instructive ECG series in massive bilateral pulmonary embolismComparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trialEvolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.Treatment of venous thromboembolism: challenging the unfractionated heparin standard.Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management.Ximelagatran: an oral direct thrombin inhibitor.The role of oral direct thrombin inhibitors in the treatment of venous thromboembolism.Management of thrombosis in cancer: primary prevention and secondary prophylaxis.Low-molecular-weight heparin for the treatment of venous thromboembolism in the elderly.
P2860
Q27006860-502D405B-10C5-4BA6-9A43-B1CF44292E8AQ28072799-728D17AE-8A96-47B4-B88D-4C3EDB7050E8Q28072833-BF4369A1-0D86-4078-9150-839C385C7BFAQ28079081-8C68B287-7592-4444-91EB-EFEB6DFE7609Q28183958-ECA20FDA-D65B-4B95-A2B2-E1B309314E2CQ33345517-42913F67-CEC1-455A-AC9D-41F170FC744BQ33364825-63DE34FF-5100-4274-BE7D-8AF280BE23E6Q33365707-60ACAEA7-1E93-43A3-88D6-1F238C316340Q33369274-D853BFB8-76B5-4EFE-951E-34B0CEAC67BBQ33590496-EE00D118-4205-4DEE-BE5B-3C3EB4752F80Q33591358-670E9B24-9588-44DF-AB72-2BF6BA91274CQ33653096-7BA0BDE1-FA07-4987-820F-F3724B95697AQ34144439-73AA2E5C-E76F-4031-94E7-AEEFD28766CBQ34278849-8C499D32-D7F2-450D-8858-0BDA074AE4B5Q34278856-7E133E05-EBC9-4B17-A9C0-1EFE86EC4477Q34351113-C8F85B8B-17D1-44F7-9535-80DFB400A501Q34351118-DCFAB86A-784C-4A7C-AD03-7E091FB855BEQ34439986-FBA490D3-CB66-468F-A545-5CC7AC0FD496Q34492516-8BC263CB-FCA4-467F-BBE5-51C440E86064Q34593514-EC61A6B2-D6D7-4824-98A1-241364CB6557Q34648639-22B03AC8-8567-415A-AD48-3ABE85070CEAQ34659817-E37DA7FA-5769-4847-BCB3-9B95531073CBQ34875662-4764D128-E3DD-4C88-89E0-2E1950674D05Q34963687-C303B022-ABDD-45DD-96C6-B6B35D5E5B0BQ35057400-B23BEB63-ED74-4FF2-B357-8434546A16E5Q35096649-26D332DF-180F-410C-B761-C24E764D2510Q35179215-E1A225B1-D3BD-4AC7-837F-718BD6EBADAAQ35189289-09B959B2-0C2D-4BEF-8F11-B15F7D2E8E2DQ35206751-ACA3BD1A-EE2E-408E-A674-9426455EE42BQ35535961-3D505C0A-BF15-4852-9543-E8242F4A0C51Q35547228-1FD7952D-CA83-4246-A1A0-5C330A6066CFQ35584375-38C24118-D810-4612-B3DC-583FEC74B3B6Q35654467-69165EEF-28E6-494E-AA0C-52F9F5568778Q35866092-C7342685-5893-4078-86B0-03467D580DA3Q35873521-7F61D663-9CEA-4731-8391-4B47D7AC47E7Q35878355-D5E3859B-DDF9-4663-B997-A1B7A1FEEBA7Q35895188-6E69A22E-1162-47E2-A41D-BDE9FF43CB69Q35996023-02CA60B9-FA8F-4B69-83EC-68E0B59B39FFQ36018537-B1136BFE-FEC8-434F-89BE-C335FDD26C63Q36022983-E386ECCE-276C-4E9B-81FE-68F04DA24934
P2860
Antithrombotic therapy for venous thromboembolic disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Antithrombotic therapy for venous thromboembolic disease.
@ast
Antithrombotic therapy for venous thromboembolic disease.
@en
Antithrombotic therapy for venous thromboembolic disease.
@nl
type
label
Antithrombotic therapy for venous thromboembolic disease.
@ast
Antithrombotic therapy for venous thromboembolic disease.
@en
Antithrombotic therapy for venous thromboembolic disease.
@nl
prefLabel
Antithrombotic therapy for venous thromboembolic disease.
@ast
Antithrombotic therapy for venous thromboembolic disease.
@en
Antithrombotic therapy for venous thromboembolic disease.
@nl
P2093
P1433
P1476
Antithrombotic therapy for venous thromboembolic disease.
@en
P2093
P304
P356
10.1378/CHEST.119.1_SUPPL.176S
P407
P433
P577
2001-01-01T00:00:00Z